Clinical trials: Urinary Tract Neoplasms
Cancer
Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
RATIONALE: White blood cells from donors who have been exposed to cytomegalovirus may be able to help prevent this infection from occurring in patients who are undergoing bone marrow or peripheral stem cell transplantation.
- Trial name
- NCT00002673
- Testing
- infection prophylaxis and management
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Kidney Cancer, Melanoma (Skin)
Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
RATIONALE: Biological therapies such as flt3L and CD40-ligand use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00020540
- Testing
- recombinant CD40-ligand, recombinant flt3 ligand
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Ewing's Family Tumors, Renal Tumors
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
This is a standard of care treatment guideline for high risk or relapsed solid tumors or CNS tumors consisting of a busulfan, melphalan, thiotepa conditioning (for solid tumors) or carboplatin and thiotepa conditioning (for CNS…
- Conditions
- Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma
- Trial name
- NCT01505569
- Testing
- Ifosfamide, Etoposide, Mesna
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
B-cell Acute Lymphoblastic Leukemia, Lymphoma
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Lymphoma, Myeloid Leukemia, Multiple Myeloma
- Trial name
- NCT03638206
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Shenzhen BinDeBio Ltd.
Bladder Cancer
Open Versus Robot Assisted Radical Cystectomy With Totally Intracorporeal Urinary Diversion.
This prospective randomized study is designed to provide high level of evidence supporting superiority of robot assisted (RA) versus open (O) radical cystectomy (RC).
- Trial name
- NCT03434132
- Testing
- Open or robotic radical cystectomy
- Where
- Italy
- Volunteers
- 116 people
- Sponsor
- Regina Elena Cancer Institute
Male Erectile Disorder, Prostate Cancer
Focal Therapy for Prostate Cancer Using HIFU
RATIONALE: Prospective trials using hemi-ablation with high intensity focused ultrasound (HIFU) (Sonablate 500) have demonstrated feasibility, safety, and encouraging functional outcomes and early cancer control with 90% of men…
- Conditions
- Male Erectile Disorder, Prostate Cancer, Therapy-related Toxicity, Urinary Incontinence
- Trial name
- INDEX (NCT01194648)
- Testing
- questionnaire administration, assessment of therapy complications, high-intensity focused ultrasound ablation
- Where
- United Kingdom
- Volunteers
- 354 people
- Sponsor
- University College, London
Urinary Incontinence
Conservative Treatment of Postprostatectomy Incontinence
The primary purpose of this study is to test the effectiveness, impact on quality of life, and durability of non-surgical therapies for incontinence persisting at least one year after surgery.
- Trial name
- NCT00212264
- Testing
- Behavioral Therapy, Pelvic Floor Electrical Stimulation, Biofeedback
- Where
- United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs)
Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China
The goal of this observational study is to validate the EQ-5D-Y-3L and EQ-5D-Y-5L in measuring health-related quality of life (HRQoL) for paediatric patients with different health conditions in China.
- Conditions
- Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs), Pneumonia Childhood, Neuroblastoma (NB)
- Trial name
- NCT06873672
- Where
- China
- Volunteers
- 360 people
- Sponsor
- RenJi Hospital
Kidney Cancer
Renal Cancer Detection Using Convolutional Neural Networks
We aim to experiment and implement various deep learning architectures in order to achieve human-level accuracy in Computer-aided diagnosis (CAD) systems.
- Trial name
- RCCCNN (NCT03857373)
- Where
- Denmark
- Volunteers
- 5,000 people
- Sponsor
- Nessn Azawi
Von Hippel Lindau, Von Hippel Lindau Disease
Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial
The BELIEVE-VHL Trial is a prospective real-life study designed to evaluate the therapeutic effects, benefits, and adverse effects of belzutifan, as well as the timing of treatment response and disease progression in patients…
- Conditions
- Von Hippel Lindau, Von Hippel Lindau Disease, Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma, Hemangioblastoma (HB) of the Central Nervous System (CNS)
- Trial name
- BELIEVE-VHL (NCT07167329)
- Testing
- Belzutifan
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- José Claudio Casali da Rocha
Childhood Acute Lymphoblastic Leukemia, Childhood Rhabdomyosarcoma
Evaluating Dactinomycin and Vincristine in Young Patients With Cancer
This laboratory study is evaluating how well dactinomycin and vincristine work in treating young patients with cancer. Studying samples of blood and urine in the laboratory from patients with cancer may help doctors learn how…
- Conditions
- Childhood Acute Lymphoblastic Leukemia, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Ewing Sarcoma
- Trial name
- NCT00674193
- Testing
- pharmacological study, laboratory biomarker analysis
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 158 people
- Sponsor
- Children's Oncology Group
Sarcoma, Multiple Myeloma
Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence
Positron Emission Tomography (PET) is a specialised nuclear medicine procedure that uses positron emitting radiolabeled tracer molecules to measure biological activity.
- Conditions
- Sarcoma, Multiple Myeloma, Testicular Neoplasms, Ovarian Neoplasms
- Trial name
- NCT00123773
- Testing
- Positron Emission Tomography
- Where
- Canada
- Volunteers
- 1,075 people
- Sponsor
- AHS Cancer Control Alberta
Kidney Cancers, Prostate Cancer
Assessment of Intelligent Algorithms for Detection, Diagnosis and Risk Stratification of Tumors of the Kidney and Prostate
The COMFORT study will evaluate an artificial intelligence-based platform developed to support the clinical assessment of kidney and prostate cancer.
- Trial name
- COMFORT (NCT07888322)
- Testing
- Medical Reading, AI assisted Medical reading
- Where
- 6 sites in Germany, Greece and 2 more
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Aristotle University Of Thessaloniki
Renal Cell Carcinoma
Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)
The goal of this clinical research study is to learn if Sutent® (sunitinib malate), given before surgery, can help control renal cell carcinoma. The safety of sunitinib malate will also be studied.
- Trial name
- NCT00715442
- Testing
- Sunitinib, Nephrectomy
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Heart Cancer, Kidney Cancer
Cancer Development In Organ Transplant Recipients
The investigators will determine the cancer risk in organ transplant recipients compared to the general population with the help of statistical analysis.
- Conditions
- Heart Cancer, Kidney Cancer, Lung Cancer, Pancreas Cancer
- Trial name
- NCT02333279
- Where
- Switzerland
- Volunteers
- 1,800 people
- Sponsor
- University of Zurich
Neuroblastoma, Medulloblastoma
Molecular-Guided Therapy for Childhood Cancer
The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup.
- Conditions
- Neuroblastoma, Medulloblastoma, Glioma, Ependymoma
- Trial name
- NCT02162732
- Testing
- Guided Therapy
- Where
- 19 sites in United States, Lebanon
- Volunteers
- 186 people
- Sponsor
- Giselle Sholler
Bladder Adenocarcinoma, Bladder Squamous Cell Carcinoma
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
This phase I trial studies the side effects and best dose of vaccine therapy given directly into the bladder in treating patients who are undergoing surgery to remove all or part of the bladder.
- Conditions
- Bladder Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma
- Trial name
- NCT00072137
- Testing
- Recombinant Fowlpox-TRICOM Vaccine, Recombinant Fowlpox GM-CSF Vaccine Adjuvant, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Urethral Cancer
Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium
RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth of urothelial cancer. PURPOSE: This randomized phase I trial is studying how well low-dose interferon alfa works in treating patients…
- Trial name
- NCT00082719
- Testing
- Recombinant Interferon Alfa
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors, CNS Tumors
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain…
- Trial name
- STARTRK-NG (NCT02650401)
- Testing
- Entrectinib
- Where
- 26 sites in United States, Canada and 7 more
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Renal Cell Carcinoma
Pemetrexed Plus Gemcitabine in Renal Cell Cancer
Primary Objective: To determine the clinical activity of Pemetrexed + Gemcitabine in non-clear cell renal cell cancer (RCC). Clinical activity will take into account response rate and progression free survival (PFS).
- Trial name
- NCT00491075
- Testing
- Pemetrexed, Gemcitabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center